Omid Seidizadeh , Andrea Cairo , Maha Othman , Flora Peyvandi
{"title":"Global prevalence of platelet-type von Willebrand disease","authors":"Omid Seidizadeh , Andrea Cairo , Maha Othman , Flora Peyvandi","doi":"10.1016/j.rpth.2025.102682","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Platelet-type von Willebrand disease (PT-VWD) is a rare autosomal dominant disorder. It is caused by gain-of-function gene variants in the platelet <em>GP1BA</em>, which results in excessive binding between GPIbα and von Willebrand factor (VWF). The prevalence of PT-VWD is unknown.</div></div><div><h3>Objectives</h3><div>To establish the worldwide and within distinct ethnic groups prevalence of PT-VWD.</div></div><div><h3>Methods</h3><div>We used available exome and genome sequencing data of 807,162 (730,947 exomes and 76,215 genomes) subjects from the Genome Aggregation Database (gnomAD-v4.1).</div></div><div><h3>Results</h3><div>Among the 1,614,324 alleles analyzed in the gnomAD population, there were 1397 distinct <em>GP1BA</em> variants. Of them, 4 variants (p.Arg127Gln, p.Leu194Phe, p.Gly249Val, and p.Met255Ile) have been previously reported to cause PT-VWD. Considering these 4 known pathogenic variants, we estimated a global PT-VWD prevalence of 136 cases/10<sup>6</sup>. The highest estimated prevalence of PT-VWD was found in Africans/African Americans (160/10<sup>6</sup>), Finnish (156/10<sup>6</sup>), Europeans (149/10<sup>6</sup>), and South Asians (110/10<sup>6</sup>), followed by Ashkenazi Jewish (68/10<sup>6</sup>) and East Asian (45/10<sup>6</sup>) ethnicities. In the population with no assigned ethnicity, a prevalence of 126/10<sup>6</sup> was estimated. Since no pathogenic <em>GP1BA</em> variants that were previously reported to cause PT-VWD were found in Admixed American and Middle Eastern ethnicities, we were unable to estimate the PT-VWD prevalence in these 2 populations. We found a global prevalence of 2.5/10<sup>6</sup> for severe PT-VWD and 134/10<sup>6</sup> for the mild form.</div></div><div><h3>Conclusion</h3><div>This population-based genetic epidemiology analysis indicates a substantially higher than expected frequency of PT-VWD. This novel finding suggests that a large number of PT-VWD patients are still under- or misdiagnosed.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 1","pages":"Article 102682"},"PeriodicalIF":3.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Practice in Thrombosis and Haemostasis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2475037925000068","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Platelet-type von Willebrand disease (PT-VWD) is a rare autosomal dominant disorder. It is caused by gain-of-function gene variants in the platelet GP1BA, which results in excessive binding between GPIbα and von Willebrand factor (VWF). The prevalence of PT-VWD is unknown.
Objectives
To establish the worldwide and within distinct ethnic groups prevalence of PT-VWD.
Methods
We used available exome and genome sequencing data of 807,162 (730,947 exomes and 76,215 genomes) subjects from the Genome Aggregation Database (gnomAD-v4.1).
Results
Among the 1,614,324 alleles analyzed in the gnomAD population, there were 1397 distinct GP1BA variants. Of them, 4 variants (p.Arg127Gln, p.Leu194Phe, p.Gly249Val, and p.Met255Ile) have been previously reported to cause PT-VWD. Considering these 4 known pathogenic variants, we estimated a global PT-VWD prevalence of 136 cases/106. The highest estimated prevalence of PT-VWD was found in Africans/African Americans (160/106), Finnish (156/106), Europeans (149/106), and South Asians (110/106), followed by Ashkenazi Jewish (68/106) and East Asian (45/106) ethnicities. In the population with no assigned ethnicity, a prevalence of 126/106 was estimated. Since no pathogenic GP1BA variants that were previously reported to cause PT-VWD were found in Admixed American and Middle Eastern ethnicities, we were unable to estimate the PT-VWD prevalence in these 2 populations. We found a global prevalence of 2.5/106 for severe PT-VWD and 134/106 for the mild form.
Conclusion
This population-based genetic epidemiology analysis indicates a substantially higher than expected frequency of PT-VWD. This novel finding suggests that a large number of PT-VWD patients are still under- or misdiagnosed.